Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Polynovo ( (AU:PNV) ).
PolyNovo Limited has reported a change in the indirect shareholding of director Leon Hoare, as disclosed to the ASX. Hoare, through his BT Super personal superannuation account, increased his beneficial holding in PolyNovo by acquiring 30,000 fully paid ordinary shares in an on-market trade.
Following the transaction on 25 February 2026, Hoare’s BT Super holding rose from 211,344 to 241,344 shares, while his spouse’s separate holding remains at 904,665 shares. The purchase, valued at $28,071.92 at $0.935 per share, signals continued personal investment by the director but does not alter the company’s capital structure or disclose any related contractual changes.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.80 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology sector, focusing on wound care and tissue regeneration products. The company develops and markets advanced polymer-based solutions for surgical and reconstructive applications, targeting hospitals and specialist clinics in Australia and international markets.
Average Trading Volume: 2,104,442
Technical Sentiment Signal: Sell
Current Market Cap: A$642.5M
Learn more about PNV stock on TipRanks’ Stock Analysis page.